Mankind Pharma Ltd (MANKIND) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Mankind Pharma Ltd stock ₹2,321, price ₹2,518, that is 7.8% below the price, quality 53 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
42‑month range ₹1,322 – ₹2,997 · fair‑value band ₹1,348 – ₹3,018 · the ₹2,518 price screens above the ₹2,321 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Mankind Pharma in your weekly email
Every Wednesday you see whether Mankind Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally.
Show moreShow less
The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc.
It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.
In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services.
It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names.
Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Stock analysis
Mankind Pharma Ltd (MANKIND) currently trades at ₹2,518, while our model-based Fair Value estimate is ₹2,321, so the stock looks roughly fairly valued today (gap 8.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹1,283 per share, and 0 of the 26 models we run sit above the ₹2,518 price.
Bear case: the Economic Profit group reads lowest at ₹392.15, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹1,348 (bear) to ₹3,018 (bull), the price of ₹2,518 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Mankind Pharma Ltd reported revenue of ₹143B in FY2026 versus ₹77.8B in FY2022, a compound +16.4%/yr. Reported net income was ₹19.1B in FY2026, compounding +7.5%/yr from FY2022.
Key figures
Market cap ₹1.0T (≈ $11.0B) Large · P/E ratio 42.9 · P/S ratio 6.77 · EPS (TTM) ₹58.71 · Dividend yield 0.0% · Net margin 14.6% · Return on equity 13.6% · Return on assets (EBIT) 15.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, MANKIND screens cheaper than that median.
Fair Value models
Bear₹1,348Fair Value ₹2,321Bull₹3,018
Price ₹2,518 · Downside -7.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹35.39 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+17.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.9%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 19%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +26.4% a year for the price and +6.6% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 552 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−7.8% · Above median
Profitability
Return on equity (12 months)13.6% · Above median
Return on assets6.8% · Above median
Net margin (12 months)14.6% · Above median
Operating margin (12 months)21.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.3% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Mankind Pharma Ltd (MANKIND) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ₹2,321 versus a price of ₹2,518, about 8% lower (fairly valued).
What is the fair value of MANKIND?
Our model-based fair value for Mankind Pharma Ltd is ₹2,321 (as of Nov 2, 2026), built from audited fundamentals. The current price: ₹2,518.
What is the quality score of MANKIND?
Mankind Pharma Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mankind Pharma Ltd (MANKIND)?
Our model-based price target is the fair value of ₹2,321 (as of Nov 2, 2026) from 26 valuation models. Cautious scenario ₹1,348, optimistic scenario ₹3,018. It is a calculation from audited fundamentals, not an analyst target.
What is the Mankind Pharma Ltd stock forecast for 2026?
Our models put fair value at ₹2,321, about 8% lower versus a price of ₹2,518 (fairly valued). Cautious scenario ₹1,348, optimistic scenario ₹3,018. The calculation is refreshed regularly with new filings.
What is the revenue of Mankind Pharma Ltd (MANKIND)?
Mankind Pharma Ltd reported trailing-twelve-month revenue of about ₹154B (latest available figure, as of Nov 2, 2026).
Does Mankind Pharma Ltd pay a dividend?
Mankind Pharma Ltd currently shows a dividend yield of 0.04% relative to its recent price (as of Nov 2, 2026).
What growth is priced into Mankind Pharma Ltd (MANKIND)?
For today's price to be fair in a discounted-cash-flow model, Mankind Pharma Ltd would have to grow free cash flow by +31.7 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.1 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of MANKIND use?
Our models discount Mankind Pharma Ltd at 10.4 %: a base by market capitalisation (large), damped by beta 0.45, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Mankind Pharma Ltd that is +31.7 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Mankind Pharma Ltd (MANKIND) delivered so far?
Over the past 5 years revenue at Mankind Pharma Ltd grew +18.1 % a year. The price currently implies +31.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Mankind Pharma Ltd (MANKIND) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Mankind Pharma Ltd (+31.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Mankind Pharma Ltd (MANKIND)?
The free-cash-flow yield on the price is 1.82 %: that much free cash flow Mankind Pharma Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Mankind Pharma Ltd (MANKIND)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mankind Pharma Ltd it is ₹2,321 per share (as of Nov 2, 2026), against a price of ₹2,518. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Mankind Pharma Ltd stock overvalued or undervalued in 2026?
As of Nov 2, 2026, MANKIND trades above its calculated fair value: price ₹2,518, fair value ₹2,321, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MANKIND?
No. The price is what the market pays today (₹2,518); the fair value is what the company's own numbers justify (₹2,321). For Mankind Pharma Ltd the two are ₹196.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mankind Pharma Ltd worth?
The market values Mankind Pharma Ltd at about ₹1.0T (market capitalisation, as of Nov 2, 2026). Per share that is ₹2,518; our models calculate a fair value of ₹2,321 per share.
What do the bullish and bearish scenarios say about MANKIND?
Our models span a range for Mankind Pharma Ltd: cautious scenario ₹1,348, base ₹2,321, optimistic ₹3,018 per share (as of Nov 2, 2026, price ₹2,518). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MANKIND?
Mankind Pharma Ltd trades at a price-to-earnings ratio of 42.9 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,321 is built from several models across several years. Other multiples: P/B 6.4, P/S 6.8, EV/EBITDA 26.0.
How solid is the balance sheet of Mankind Pharma Ltd (MANKIND)?
Balance-sheet figures for Mankind Pharma Ltd (as of Nov 2, 2026): return on equity 13.6%, debt of 0.17 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is MANKIND from its 52-week high?
Mankind Pharma Ltd trades at ₹2,518, about 4% below its 52-week high of ₹2,618 and 31% above the low of ₹1,927 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,321 is for.
Which stocks are comparable to Mankind Pharma Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mankind Pharma Ltd stock attractive at the current price?
The data as of Nov 2, 2026: price ₹2,518, calculated fair value ₹2,321 (−8%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MANKIND calculated?
We run Mankind Pharma Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2,321, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Mankind Pharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mankind Pharma Ltd (MANKIND)?
The closing price on Nov 5, 2026 was ₹2,518. Our model-based fair value is ₹2,321, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mankind Pharma Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹1,348 to ₹3,018) leaves room in how you read the outcome.
Key figures of Mankind Pharma Ltd
How large is the market capitalisation of Mankind Pharma Ltd (MANKIND)?
The market capitalisation of Mankind Pharma Ltd is ₹1.0T (≈ $11.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mankind Pharma Ltd (MANKIND)?
The price-to-sales ratio of Mankind Pharma Ltd is 6.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mankind Pharma Ltd (MANKIND)?
Earnings per share at Mankind Pharma Ltd are ₹58.71 (price ÷ EPS = P/E 42.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mankind Pharma Ltd (MANKIND)?
The dividend yield of Mankind Pharma Ltd is 0.0% (payout 1.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mankind Pharma Ltd (MANKIND)?
The net margin of Mankind Pharma Ltd is 14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mankind Pharma Ltd (MANKIND)?
The return on equity (ROE) of Mankind Pharma Ltd is 13.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mankind Pharma Ltd (MANKIND)?
On an EBIT basis the return on assets of Mankind Pharma Ltd is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mankind Pharma Ltd (MANKIND)?
The operating margin of Mankind Pharma Ltd is 21.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mankind Pharma Ltd (MANKIND)?
Revenue at Mankind Pharma Ltd is growing +17.3% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mankind Pharma Ltd (MANKIND)?
Earnings per share at Mankind Pharma Ltd are growing +38.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Mankind Pharma Ltd (MANKIND) carry?
The net debt of Mankind Pharma Ltd is ₹58.3B (fiscal year 2026, ≈ 3.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mankind Pharma Ltd in the live analysis
One click puts Mankind Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 2, 2026